Personalised Management of Prostate Cancer

Author:

Babu Dilip1,Sahasrabudhe Deepak1

Affiliation:

1. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA

Abstract

Despite recent advances, prostate cancer continues to be a leading cause of cancer-related death among men. While the standard management options of surgery, radiotherapy, and androgen deprivation therapy are well established, there are still significant unmet needs. For example, which patients would best be served by active surveillance at the time of diagnosis versus proceeding with definitive therapy is still not well understood. Additionally, more accurate means of monitoring patients’ responses to therapy and remission statuses following therapy are needed. Since all patients with metastatic disease ultimately progress to castration-resistant prostate cancer, new treatment options for this population are also required. As in other areas of oncology, greater personalisation of care holds the potential for more effective treatment while also reducing the risk of adverse effects and morbidity. This review addresses three topics currently under investigation related to the personalised management of prostate cancer: the use of circulating tumour cells in both diagnosis and treatment at all stages of the disease, the introduction of poly(adenosine diphosphate-ribose) polymerase inhibitors for the treatment of castration-resistant prostate cancer, and the emerging role of genomic assays for risk stratification at the time of diagnosis.

Publisher

European Medical Group

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3